CRISPR gene editing technology is advancing rapidly enough that the possibility of genetic modification for athletic performance is no longer science fiction. When it arrives, it will render the entire natural-versus-enhanced debate meaningless because the fundamental categories themselves will become incoherent.
What Gene Editing Could Target
Myostatin is a protein that limits muscle growth. Individuals with natural myostatin gene mutations develop significantly more muscle mass with less training. Gene editing could theoretically knock out or reduce myostatin expression, producing the same phenotype without any exogenous substance. Your body would grow more muscle naturally because the genetic brake has been removed.
Androgen receptor density could be upregulated, making existing testosterone more effective. Erythropoietin production could be enhanced for improved oxygen delivery. Growth hormone secretion patterns could be modified. These would all be permanent genetic changes that alter your baseline physiology without ongoing supplementation. This is a direct application of the Tony Huge Laws of Biochemistry Physics—permanently altering the foundational code to change the body’s output without continuous external input.
The Classification Collapse
Is a gene-edited athlete natural? They are not taking any substances. Their hormones are endogenous. Their muscle is built by their own physiology. But their physiology has been artificially modified at the most fundamental level. The natural-or-not binary cannot accommodate this scenario because it was designed for a world where enhancement required ongoing external inputs.
This is not a hypothetical edge case. It is a scenario that will become real within most current athletes’ lifetimes. And the fact that existing classification systems cannot handle it reveals that those systems were never measuring what they claimed to measure. They were measuring behavioral choices, specifically the choice to take certain substances, not physiological naturalness.
Why This Matters Now
The approaching obsolescence of the natural-versus-enhanced dichotomy is a reason to adopt spectrum-based thinking now. A framework that evaluates interventions based on their specific risk-benefit profiles, their reversibility, and their impact on health rather than their compliance with identity labels will survive the gene editing era. A binary framework will not.
Gene editing will be the ultimate demonstration that naturalness is a social construct, not a biological fact. The question was never whether your physiology was modified. The question was always about risk, benefit, and informed consent. Building our frameworks around those questions now will produce better outcomes both before and after the genetic revolution arrives.
Interesting Perspectives
While the core article focuses on the philosophical and categorical implications of gene editing for performance, the conversation is already expanding into more speculative and nuanced territories. Some futurists and bioethicists argue that the initial use of CRISPR in sports won’t be for creating super-athletes from scratch, but for “corrective” or “therapeutic” edits that blur the line further—for instance, editing genes to allow an athlete to recover from an injury faster, effectively giving them a permanent, enhanced healing factor. Others point to the potential for “epigenetic editing,” where gene expression is modulated without changing the underlying DNA sequence, creating a new gray area of “temporary genetic enhancement.” There’s also a growing discussion around “gene doping” detection, which may lead to a new arms race in anti-doping technology, potentially involving whole-genome sequencing of athletes at birth to establish a baseline. Furthermore, the accessibility of this technology could create a new performance divide not based on discipline or access to pharmaceuticals, but on access to capital and cutting-edge medical clinics, fundamentally altering the economics of competitive sports.
Citations & References
- This article is a forward-looking opinion piece based on the established trajectory of CRISPR-Cas9 technology and its discussed applications in enhancing physical traits. As such, it synthesizes known scientific principles with ethical forecasting, and does not cite specific clinical trials, as human genetic enhancement for athletic performance remains a theoretical domain.